This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Kimball A, Pariser D, Kricorian G, Gelfand J.Safety update from OBSERVE-5, a long-term safety surveillance registry of etanercept therapy for psoriasis. 68th Annual Meeting of the American Academy of Dermatology: abstr. P3326, 5 Mar 2010. Available from: URL: http://www.aad.org/meetings/annual/
Paller A, Pariser D, Siegfried E, Kricorian G.Safety and efficacy of etanercept treatment in children and adolescents with plaque psoriasis: 96-week results of open-label extension study. 68th Annual Meeting of the American Academy of Dermatology: abstr. P506, 5 Mar 2010. Available from: URL: http://www.aad.org/meetings/annual/
Tyring S, Frankel E, Rozzo S, Gu Y.Long-term clinical trial safety experience with adalimumab 40 mg every other week for treatment of moderate to severe psoriasis. 68th Annual Meeting of the American Academy of Dermatology: abstr. P3332, 5 Mar 2010. Available from: URL: http://www.aad.org/meetings/annual/
Leonardi C, Papp K, Rozzo S, Gu Y.Long-term safety of adalimumab for psoriasis: An analysis of all adalimumab exposure in all global clinical trials. 68th Annual Meeting of the American Academy of Dermatology: abstr. P3337, 5 Mar 2010. Available from: URL: http://www.aad.org/meetings/annual/
Gordon K, Leonardi C, Reich K, Yeilding N.The ustekinumab safety experience in patients with moderate to severe psoriasis: Results from pooled analyses of phase II and phase III clinical trial data. 68th Annual Meeting of the American Academy of Dermatology: abstr. P3336, 5 Mar 2010. Available from: URL: http://www.aad.org/meetings/annual/
Rights and permissions
About this article
Cite this article
News from AAD. React. Wkly. 1298, 4–5 (2010). https://doi.org/10.2165/00128415-201012980-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201012980-00009